arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AVENUE THERAPEUTICS, INC.

ATXI
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

AVENUE THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin -219.6%
ROIC -132.9% ↗
FCF / Share $-0.59 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.40M
— —
Net Income Profit after all expenses
$-2.91M
↑ +75.0% —
FCF / Share Free cash flow per share
$-0.59
↑ +91.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns ↓
4
Cash Quality ↓
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 44 quarters